ASH 2018 | Reversible BTK inhibitor ARQ 531 for CLL and NHL

VJHemOnc is committed to improving our service to you

Jennifer Woyach

ARQ 531 is a reversible inhibitor of wild type and C481S-mutant BTK. Here, Jennifer Woyach, MD, of the Ohio State University College of Medicine, Columbus, OH, tells us about the promising preliminary data from the Phase I dose escalation study (NCT03162536) across a variety of B-cell malignancies.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter